DNA Link Inc (127120) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DNA Link Inc (127120) has a cash flow conversion efficiency ratio of -0.060x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-5.37 Billion ≈ $-3.64 Million USD) by net assets (₩89.37 Billion ≈ $60.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is DNA Link Inc worth for the company's overall valuation and market capitalisation.
DNA Link Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DNA Link Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DNA Link Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DNA Link Inc ranked by their cash flow conversion efficiency. Explore DNA Link Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fuxin Dare Automotive Parts Co Ltd
SHE:300473
|
0.056x |
|
Bergman & Beving AB (publ)
ST:BERG-B
|
0.065x |
|
ZYLOX-TONBRDG.MED.TECH.H1
F:818
|
N/A |
|
SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
NASDAQ:HDL
|
0.087x |
|
Wuhan LinControl Automotive Electronics Co. Ltd. A
SHG:688667
|
0.053x |
|
Shandong Huatai Paper Industry Shareholding Co Ltd
SHG:600308
|
0.023x |
|
Shenzhen Grandland Decoration Group Co Ltd
SHE:002482
|
0.133x |
|
Shenzhen Jieshun Science and Technology Industry Co Ltd
SHE:002609
|
0.059x |
Annual Cash Flow Conversion Efficiency for DNA Link Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of DNA Link Inc from 2011 to 2025. View 127120 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩68.59 Billion ≈ $46.48 Million |
₩-9.39 Billion ≈ $-6.36 Million |
-0.137x | +49.49% |
| 2024-12-31 | ₩25.03 Billion ≈ $16.96 Million |
₩-6.78 Billion ≈ $-4.60 Million |
-0.271x | -41.54% |
| 2023-12-31 | ₩26.28 Billion ≈ $17.81 Million |
₩-5.03 Billion ≈ $-3.41 Million |
-0.191x | -686.44% |
| 2022-12-31 | ₩27.89 Billion ≈ $18.90 Million |
₩910.27 Million ≈ $616.88K |
0.033x | +116.64% |
| 2021-12-31 | ₩32.77 Billion ≈ $22.21 Million |
₩-6.43 Billion ≈ $-4.36 Million |
-0.196x | -993.88% |
| 2020-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩849.38 Million ≈ $575.62K |
0.022x | +116.32% |
| 2019-12-31 | ₩9.66 Billion ≈ $6.55 Million |
₩-1.30 Billion ≈ $-880.41K |
-0.134x | -64.54% |
| 2018-12-31 | ₩19.60 Billion ≈ $13.29 Million |
₩-1.60 Billion ≈ $-1.09 Million |
-0.082x | +22.37% |
| 2017-12-31 | ₩23.66 Billion ≈ $16.03 Million |
₩-2.49 Billion ≈ $-1.69 Million |
-0.105x | +94.93% |
| 2016-12-31 | ₩1.82 Billion ≈ $1.23 Million |
₩-3.77 Billion ≈ $-2.55 Million |
-2.076x | -523.69% |
| 2015-12-31 | ₩11.20 Billion ≈ $7.59 Million |
₩-3.73 Billion ≈ $-2.53 Million |
-0.333x | -1698.26% |
| 2014-12-31 | ₩7.73 Billion ≈ $5.24 Million |
₩-143.14 Million ≈ $-97.00K |
-0.019x | +58.15% |
| 2012-12-31 | ₩17.70 Billion ≈ $12.00 Million |
₩-783.00 Million ≈ $-530.63K |
-0.044x | +79.15% |
| 2011-12-31 | ₩11.52 Billion ≈ $7.81 Million |
₩-2.44 Billion ≈ $-1.66 Million |
-0.212x | -- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more